📊 CLYM Key Takeaways
Is Climb Bio, Inc. (CLYM) a Good Investment?
Climb Bio is a pre-revenue biopharmaceutical company with significant cash burn (-$54.4M operating cash flow) and no meaningful revenue generation, characteristic of early-stage drug development. While the company maintains adequate liquidity ($35.7M cash) and minimal debt, the combination of substantial operating losses (-$67.9M), negative returns on equity (-37.3%) and assets (-35.7%), and accelerating cash consumption presents material near-term survival risk without successful clinical advancement or financing.
Climb Bio’s fundamentals reflect a typical pre-revenue biotech profile: no commercial revenue, persistent operating and free cash flow losses, and no visible margin support yet. The balance sheet is the main offsetting strength, with high liquidity, minimal liabilities, and no long-term debt, which gives the company funding flexibility despite continued cash burn.
Why Buy Climb Bio, Inc. Stock? CLYM Key Strengths
- Strong liquidity position with 15.16x current ratio and $35.7M cash reserves
- No long-term debt, minimizing financial obligations and leverage risk
- Improved diluted EPS trend (+42.5% YoY) suggesting share count management
- Very strong liquidity, with current and quick ratios of 15.16x and $35.69M in cash
- Clean balance sheet with essentially no leverage and only $7.27M in total liabilities
- EPS loss improved year over year, suggesting some per-share loss compression despite ongoing operating losses
CLYM Stock Risks: Climb Bio, Inc. Investment Risks
- Pre-revenue stage with no commercial products generating cash flow
- Severe ongoing operating losses (-$67.9M) with negative free cash flow (-$54.5M)
- Estimated 7-8 month cash runway at current burn rate without additional capital raises
- Negative ROE (-37.3%) and ROA (-35.7%) indicate value destruction
- 7 Form 4 filings in 90 days may indicate insider concern or volatility
- No revenue base, making growth quality and operating leverage impossible to validate
- Sustained cash burn, with operating cash flow of -$54.36M and free cash flow of -$54.54M
- Large annual net and operating losses indicate dependence on external capital if commercialization is delayed
Key Metrics to Watch
- Quarterly operating cash flow burn rate and cash runway extension
- Clinical trial advancement milestones and regulatory pathway progress
- Capital raise announcements and dilution impact on shareholder value
- Operating expense trends and development spending efficiency
- Quarterly operating cash burn relative to cash balance
- Any emergence of revenue or major reduction in operating loss
Climb Bio, Inc. (CLYM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.16x current ratio provides a solid financial cushion.
CLYM Profit Margin, ROE & Profitability Analysis
CLYM vs Healthcare Sector: How Climb Bio, Inc. Compares
How Climb Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Climb Bio, Inc. Stock Overvalued? CLYM Valuation Analysis 2026
Based on fundamental analysis, Climb Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Climb Bio, Inc. Balance Sheet: CLYM Debt, Cash & Liquidity
CLYM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Climb Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.53 indicates the company is currently unprofitable.
CLYM Revenue Growth, EPS Growth & YoY Performance
Climb Bio, Inc. Dividends, Buybacks & Capital Allocation
CLYM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Climb Bio, Inc. (CIK: 0001768446)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLYM
What is the AI rating for CLYM?
Climb Bio, Inc. (CLYM) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLYM's key strengths?
Claude: Strong liquidity position with 15.16x current ratio and $35.7M cash reserves. No long-term debt, minimizing financial obligations and leverage risk. ChatGPT: Very strong liquidity, with current and quick ratios of 15.16x and $35.69M in cash. Clean balance sheet with essentially no leverage and only $7.27M in total liabilities.
What are the risks of investing in CLYM?
Claude: Pre-revenue stage with no commercial products generating cash flow. Severe ongoing operating losses (-$67.9M) with negative free cash flow (-$54.5M). ChatGPT: No revenue base, making growth quality and operating leverage impossible to validate. Sustained cash burn, with operating cash flow of -$54.36M and free cash flow of -$54.54M.
What is CLYM's revenue and growth?
Climb Bio, Inc. reported revenue of N/A.
Does CLYM pay dividends?
Climb Bio, Inc. does not currently pay dividends.
Where can I find CLYM SEC filings?
Official SEC filings for Climb Bio, Inc. (CIK: 0001768446) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLYM's EPS?
Climb Bio, Inc. has a diluted EPS of $-0.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CLYM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Climb Bio, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CLYM stock overvalued or undervalued?
Valuation metrics for CLYM: ROE of -37.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CLYM stock in 2026?
Our dual AI analysis gives Climb Bio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLYM's free cash flow?
Climb Bio, Inc.'s operating cash flow is $-54.4M, with capital expenditures of $186.0K.
How does CLYM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -37.3% (avg: 15%), current ratio 15.16 (avg: 2).